FindTrial
Sign In

A feasibility study on the use of hair and dry blood spot drug concentrations in predicting the efficacy, safety, and emergence of drug resistance in antiretroviral therapy

A feasibility study on the use of hair and dry blood spot drug concentrations in predicting the efficacy, safety, and emergence of drug resistance in antiretroviral therapy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600125526
Enrollment
Unknown
Registered
2026-05-27
Start date
2026-05-27
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

AIDS

Interventions

AIDS Observation Group:None

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Age range: 18 - 65 years old, gender not limited; 2. HIV patients who have received antiretroviral therapy (ART) for at least 12 months.

Exclusion criteria

Exclusion criteria: 1. Patients who have not reached the legal age (such as under 18 years old) or who are unable to understand and sign the informed consent form. 2. Patients with other serious complications or diseases, such as active liver disease, kidney disease, heart disease, uncontrolled diabetes, etc. 3. Patients who are participating in other clinical studies. 4. Patients with severe mental disorders who cannot cooperate with the research or are impossible to consistently follow ART treatment.

Design outcomes

Primary

MeasureTime frame
Hair and dry blood spot drug concentrations;—

Countries

China

Contacts

Public ContactChen Liyu

West China Hospital of Sichuan University

14491291@qq.com+86 28 8542 1179

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 11, 2026